SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Achilles Therapeutics plc – ‘6-K’ for 8/9/22

On:  Tuesday, 8/9/22, at 4:36pm ET   ·   For:  8/9/22   ·   Accession #:  950170-22-16122   ·   File #:  1-40299

Previous ‘6-K’:  ‘6-K’ on / for 6/28/22   ·   Next:  ‘6-K’ on / for 11/8/22   ·   Latest:  ‘6-K’ on / for 11/13/23   ·   1 Reference:  By:  Achilles Therapeutics plc – ‘F-3’ on 11/8/22

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/09/22  Achilles Therapeutics plc         6-K         8/09/22    4:2.3M                                   Donnelley … Solutions/FA

Current, Quarterly or Annual Report by a Foreign Issuer   —   Form 6-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Current, Quarterly or Annual Report by a Foreign    HTML     46K 
                Issuer                                                           
 2: EX-99.1     Miscellaneous Exhibit                               HTML    295K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML   1.50M 
 4: EX-99.3     Miscellaneous Exhibit                               HTML    453K 


‘6-K’   —   Current, Quarterly or Annual Report by a Foreign Issuer


This is an HTML Document rendered as filed.  [ Alternative Formats ]



  6-K  

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of August 2022

Commission File Number: 001-40299

 

 

Achilles Therapeutics plc

(Exact name of registrant as specified in its charter)

 

 

245 Hammersmith Road

London W6 8PW

United Kingdom

Tel: +44 (0)20 8154 4600

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

 


 

Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

On August 9, 2022, Achilles Therapeutics plc (“Achilles” or the “Company”) issued a press release, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 6-K, reporting its financial results for the three and six month periods ended June 30, 2022 and providing an update on recent business highlights. Furnished (i) as Exhibit 99.2 to this Current Report on Form 6-K are the Company’s unaudited consolidated financial statements for the three and six month periods ended June 30, 2022 and (ii) as Exhibit 99.3 to this Current Report on Form 6-K is the Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three and six month periods ended June 30, 2022.

The statements contained in this “Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights” section of this Current Report on Form 6-K and the information contained in Exhibits 99.1 and 99.2 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.
 

 

 


 

INDEX TO EXHIBITS

 

Number

 

Description

 

 

99.1

 

Press Release of Achilles Therapeutics plc dated August 9, 2022.

 

 

99.2

 

Unaudited Condensed Consolidated Financial Statements of Achilles Therapeutics plc for the three and six month periods ended June 30, 2022.

 

 

99.3

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations of Achilles Therapeutics plc for the three and six month periods ended June 30, 2022.

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

 

ACHILLES THERAPEUTICS PLC

 

 

 

 

Date: August 9, 2022

 

 

 

By:

 

/s/ Robert Coutts

 

 

 

 

 

 

Robert Coutts

 

 

 

 

 

 

Chief Financial Officer

 

 



Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘6-K’ Filing    Date    Other Filings
Filed on / For Period end:8/9/22None on these Dates
6/30/22
 List all Filings 


1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/08/22  Achilles Therapeutics plc         F-3                    7:1.3M                                   Donnelley … Solutions/FA
Top
Filing Submission 0000950170-22-016122   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 8:42:32.1am ET